AR039670A1 - Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad - Google Patents

Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad

Info

Publication number
AR039670A1
AR039670A1 ARP030101431A ARP030101431A AR039670A1 AR 039670 A1 AR039670 A1 AR 039670A1 AR P030101431 A ARP030101431 A AR P030101431A AR P030101431 A ARP030101431 A AR P030101431A AR 039670 A1 AR039670 A1 AR 039670A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
aryl
independently
heteroaryl
Prior art date
Application number
ARP030101431A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR039670A1 publication Critical patent/AR039670A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) en la cual R1 es H o alquilo C1-6; cada uno de R2 y R3 es, independientemente, H, hidroxi, alquilo C1-6, alcoxi C1-6, halógeno, carboxamido, carboalcoxi C2-6, perfluoralquilo C1-6, ciano, alcansulfonamido C1-6, alcansulfonilo C1-6, alcanamido C1-6, amino, alquilamino C1-6, dialquilamino C1-6 por porción de alquilo, perfluoralcoxi C1-6, alcanoiloxi C2-6, alcanoilo C2-6, aroilo C6-8, arilo C5-7, un grupo alquilarilo C6-13 con 5 a 7 átomos de C en la porción arilo, un grupo heteroarilo de 5 a 7 miembros o un grupo alquilheteroarilo de 6 a 13 miembros con 5 a 7 miembros en la porción heteroarilo, donde cualquier sustituyente R2 o R3 que tenga una porción arilo o heteroarilo puede estar optativamente sustituido en la porción arilo o heteroarilo con 1 a 3 sustituyentes independientemente seleccionados entre un átomo de halógeno, un grupo alquilo C1-6 o un grupo alcoxi C1-6; cada uno de R4 y R5 es, independientemente, H o alquilo C1-6 o R4 y R5, tomados junto con los C a los cuales están unidos, forman una porción cíclica seleccionada entre un cicloalcano C4-8, cicloalqueno C4-8, alcano bicíclico enlazado de C5-10, alqueno bicíclico enlazado C5-10, pirano o tiopirano, en los cuales el átomo de S está optativamente oxidado al sulfóxido o la sulfona, donde la porción cíclica formada por R4 y R5 puede estar optativamente sustituida con 1 a 3 sustituyentes independientemente seleccionados entre un átomo de halógeno, un grupo alquilo C1-6, un grupo alcoxi C1-6; cada uno de R6 y R7 es, independientemente, H, o alquilo C1-6 y n es 1 o 2; o una sal farmacéuticamente aceptable de los mismos.
ARP030101431A 2002-04-25 2003-04-24 Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad AR039670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37615302P 2002-04-25 2002-04-25

Publications (1)

Publication Number Publication Date
AR039670A1 true AR039670A1 (es) 2005-03-02

Family

ID=29270769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101431A AR039670A1 (es) 2002-04-25 2003-04-24 Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad

Country Status (17)

Country Link
US (2) US7071185B2 (es)
EP (1) EP1497294B1 (es)
JP (1) JP2005529894A (es)
CN (2) CN1955180A (es)
AR (1) AR039670A1 (es)
AT (1) ATE358129T1 (es)
AU (1) AU2003243160B2 (es)
BR (1) BR0309463A (es)
CA (1) CA2482455A1 (es)
DE (1) DE60312838T2 (es)
DK (1) DK1497294T3 (es)
ES (1) ES2282652T3 (es)
MX (1) MXPA04010374A (es)
PT (1) PT1497294E (es)
SI (1) SI1497294T1 (es)
TW (1) TW200307682A (es)
WO (1) WO2003091251A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
TW200635926A (en) * 2004-11-05 2006-10-16 Wyeth Corp Metabolites of ceratin [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
WO2007111982A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
EP1998781A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Treatment of pain
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
AU2011212930B2 (en) 2010-02-04 2016-02-11 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
EP2824106B1 (en) * 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
CN104995191A (zh) 2012-09-14 2015-10-21 艾伯维德国有限责任两合公司 三环喹啉和喹喔啉衍生物
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US10407381B2 (en) 2015-01-29 2019-09-10 The Board Of Trustees Of The University Of Illinois Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists
BR112018001707A2 (pt) * 2015-07-31 2018-09-18 Arena Pharm Inc agonistas de receptor 5-ht2c e composições e métodos de uso
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
US10829877B2 (en) * 2018-08-27 2020-11-10 Nippon Mayer Ltd. Warp knitting machine, warp knitted fabric manufacturing method and warp knitted fabric

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US50300A (en) * 1865-10-03 John h
US422524A (en) * 1890-03-04 Marion c
US422657A (en) * 1890-03-04 Cane cutter or disintegrator
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
GB1120462A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma 3-alkoxy-2h-fluoreno[1,9-ef]-1,4-diazepine 1-oxides and derivatives thereof
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
DE2443567C3 (de) * 1974-09-12 1980-04-10 Hoechst Ag, 6000 Frankfurt U3,4,7,8-Hexahydro-(6H)-pyrido- [U3-ef] -1,5benzodiazepin-2-one, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SU930902A1 (ru) 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
EP0357417A1 (en) 1988-09-01 1990-03-07 Glaxo Group Limited Lactam derivatives
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
EP0480939B1 (en) 1989-06-09 1995-01-25 The Upjohn Company Heterocyclic amines having central nervous system activity
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
JPH10237073A (ja) 1996-02-02 1998-09-08 Sumitomo Pharmaceut Co Ltd 新規な置換グアニジン誘導体およびその製法
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
AU710876B2 (en) 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
JP2000505450A (ja) 1996-02-21 2000-05-09 ダーウィン・ディスカバリー・リミテッド キノロン類およびこれらの治療的使用
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
CA2324475A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
SK8192001A3 (en) 1998-12-17 2001-12-03 American Home Prod 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivatives being 5ht2c agonists
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
NZ516031A (en) 1999-06-15 2003-10-31 Bristol Myers Squibb Pharma Co Substituted heterocycle fused gamma-carbolines
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
JP2001089461A (ja) 1999-09-24 2001-04-03 Konica Corp テトラヒドロナフトジアゼピン類の製造方法及びスクアリリウム染料の製造方法
AU2001254672A1 (en) 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU2002239463A1 (en) 2000-11-03 2002-06-03 Wyeth Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
US6858604B2 (en) * 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) * 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
US6784172B2 (en) * 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR031198A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
PL366627A1 (en) 2000-12-20 2005-02-07 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
EE200300296A (et) * 2000-12-20 2003-12-15 Bristol-Myers Squibb Company Asendatud püridoindoolid kui serotoniini agonistid ja antagonistid ning nende kasutamine
BR0211559A (pt) 2001-08-06 2004-07-13 Upjohn Co Compostos, composições de ligantes tetracìclicos terapeuticamente úteis e seus usos
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents

Also Published As

Publication number Publication date
CN1955180A (zh) 2007-05-02
EP1497294A1 (en) 2005-01-19
ATE358129T1 (de) 2007-04-15
JP2005529894A (ja) 2005-10-06
DK1497294T3 (da) 2007-07-16
US20060154920A1 (en) 2006-07-13
WO2003091251A1 (en) 2003-11-06
SI1497294T1 (sl) 2007-08-31
DE60312838T2 (de) 2008-01-10
BR0309463A (pt) 2005-02-09
DE60312838D1 (de) 2007-05-10
EP1497294B1 (en) 2007-03-28
ES2282652T3 (es) 2007-10-16
CN1662534A (zh) 2005-08-31
CN100379735C (zh) 2008-04-09
AU2003243160B2 (en) 2009-02-05
US7071185B2 (en) 2006-07-04
MXPA04010374A (es) 2005-02-03
US20040019040A1 (en) 2004-01-29
TW200307682A (en) 2003-12-16
AU2003243160A1 (en) 2003-11-10
PT1497294E (pt) 2007-06-12
CA2482455A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AR039670A1 (es) Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad
AR039669A1 (es) Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad
AR039668A1 (es) Derivados[1,4] diazocino [7,8,1-hi] indol como, agentes antipsicoticos y antiobesidad
AR043633A1 (es) Ligandos de receptores de canabinoides
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
ES2071919T3 (es) Agentes antianginosos de pirazolopirimidina.
SE8106430L (sv) Karbostyrilforeningar, kompositioner innehallande dessa samt forfaranden for framstellning derav
AR050169A1 (es) Compuesto para el tratamiento de trastornos inflamatorios
PE20030922A1 (es) Derivados de piridina y quinolina
AR046845A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
AR051946A1 (es) Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
AR035666A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ATE168377T1 (de) Spiro(pyran)piperidine-derivate
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
CO5680443A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos
AR038835A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
AR041030A1 (es) Derivados de 3-hidroxi-4-(ciclil-alquilaminoalquil)-5-fenil-1h-pirazol como antagonistas de la hormona de liberacion de gonadotropina
CO4910141A1 (es) DERIVADOS DE 1-H-PIRIDO[3,4-b]INDOL-4-CARBOXAMIDA Y SU PREPARACION
KR940014397A (ko) 비사이클릭 아민 유도체
NO20055150L (no) Benzotiazolderivater som adenosin-reseptorligander
AR031196A1 (es) Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados

Legal Events

Date Code Title Description
FB Suspension of granting procedure